Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XP20B
- Development stage
- Unknown
- Lead developer
- Xanodyne Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**XP20B** was a Xanodyne-developed, oral modified-release fixed-dose analgesic tablet containing **propoxyphene** and **acetaminophen**. The formulation incorporated immediate- and sustained-release components intended to provide extended analgesia for mild to moderate pain. Xanodyne completed a randomized, double-blind, placebo-controlled Phase 3 study evaluating XP20B for pain following bunionectomy surgery. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00655291))
- Brand names
- Distalgesic
- Other names
- co-proxamolpropoxyphene + acetaminophen
02
Targets
KOR (Kappa opioid receptor)COXMOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on XP20B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XP20B.